Working… Menu

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04595409
Recruitment Status : Active, not recruiting
First Posted : October 20, 2020
Last Update Posted : August 6, 2021
Information provided by (Responsible Party):
Bioeq GmbH

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 7, 2021
Estimated Study Completion Date : March 2022